Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Vanda Pharmaceuticals (VNDA) over the last 15 years, with Q4 2025 value amounting to $102000.0.

  • Vanda Pharmaceuticals' Capital Expenditures fell 5233.64% to $102000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $998000.0, marking a year-over-year increase of 10367.35%. This contributed to the annual value of $998000.0 for FY2025, which is 10367.35% up from last year.
  • Per Vanda Pharmaceuticals' latest filing, its Capital Expenditures stood at $102000.0 for Q4 2025, which was down 5233.64% from $161000.0 recorded in Q3 2025.
  • In the past 5 years, Vanda Pharmaceuticals' Capital Expenditures ranged from a high of $436000.0 in Q1 2025 and a low of -$10000.0 during Q3 2021
  • Over the past 5 years, Vanda Pharmaceuticals' median Capital Expenditures value was $141000.0 (recorded in 2021), while the average stood at $155100.0.
  • As far as peak fluctuations go, Vanda Pharmaceuticals' Capital Expenditures plummeted by 10406.5% in 2021, and later soared by 612857.14% in 2025.
  • Over the past 5 years, Vanda Pharmaceuticals' Capital Expenditures (Quarter) stood at $134000.0 in 2021, then soared by 96.27% to $263000.0 in 2022, then fell by 3.8% to $253000.0 in 2023, then decreased by 15.42% to $214000.0 in 2024, then tumbled by 52.34% to $102000.0 in 2025.
  • Its Capital Expenditures stands at $102000.0 for Q4 2025, versus $161000.0 for Q3 2025 and $299000.0 for Q2 2025.